LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.

Photo from wikipedia

BACKGROUND AIMS Biliary tract cancers are rare, heterogeneous cancers with poor prognosis. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β "trap") fused… Click to show full abstract

BACKGROUND AIMS Biliary tract cancers are rare, heterogeneous cancers with poor prognosis. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β "trap") fused to a human IgG1 mAb blocking PD-L1, was evaluated in patients with locally advanced/metastatic chemorefractory biliary tract cancers. APPROACH RESULTS This multicenter, single-arm, open-label, phase 2 study (NCT03833661) enrolled adults with locally advanced or metastatic biliary tract cancer that was intolerant to or had failed first-line systemic platinum-based chemotherapy. Patients received 1200 mg bintrafusp alfa intravenously Q2W. Primary endpoint was confirmed objective response according to RECIST 1.1 assessed by IRC. Secondary endpoints included DOR, durable response rate, safety, PFS, and OS.Between March 2019 and January 2020, 159 patients were enrolled. Median follow-up was 16.1 (range, 0.0-19.3) months; 17 patients (10.7%; 95% CI, 6.4% -16.6%) achieved objective response. Median DOR was 10.0 (range, 1.9-15.7) months; 10 patients (6.3%; 95% CI, 3.1%- 11.3%) had a durable response (≥6 mo). Median PFS was 1.8 months (95% CI, 1.7-1.8 mo); median OS was 7.6 months (95% CI, 5.8-9.7 mo). OS rates were 57.9% (6-month) and 38.8% (12-month). Grade ≥3 AEs occurred in 26.4% of patients, including one treatment-related death (hepatic failure). Frequent grade ≥3 adverse events included anemia (3.8%), pruritus (1.9%), and increased alanine aminotransferase (1.9%). CONCLUSIONS Although this study did not meet its prespecified primary endpoint, bintrafusp alfa demonstrated clinical activity as second-line treatment in this hard-to-treat cancer, with durable responses and a manageable safety profile.

Keywords: locally advanced; biliary tract; tract cancers; bintrafusp alfa

Journal Title: Hepatology
Year Published: 2023

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.